We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Altered Gut Flora Could Indicate Parkinson's

By LabMedica International staff writers
Posted on 12 Sep 2017
In search of a early-diagnostic biomarker for Parkinson’s disease, researchers have found that specific changes in the gut microbiota could help identify the disease in its early stages, before clinical symptoms appear.

By the time Parkinson's disease manifests as the typical motor dysfunctions such as tremors or muscle rigidity, portions of the brain have already been irreversibly destroyed; the disease will have often begun already decades earlier. More...
In search of an early portent of the disease, researchers led by Paul Wilmes, professor at University of Luxembourg (Esch-sur-Alzette, Luxembourg) may now have found one in the gut: they have shown that the bacterial community in the gut of Parkinson's patients differs from that of healthy people even at a very early stage of the disease.

Experts have long been discussing the notion that Parkinson's disease originates far outside the brain. According to the "dual hit" hypothesis, a hitherto unknown pathogen intrudes into the body through two ports of entry: the nose or the gastrointestinal tract. Once there, it sets a pathological process in motion, above all the misfolding of the protein alpha-synuclein, whose function is as yet largely unknown. Among other things, it is presumed to be involved in the excretion of messengers such as dopamine. The misfolding of this protein could propagate through the nerve pathways, where - decades later - it produces the typical clumping in the dopaminergic cells, Lewy bodies, that are characteristic of Parkinson's. Ultimately, nerve cells start to die off and the typical symptoms of Parkinson's disease appear.

The researchers led by Prof. Wilmes, together with physicians Prof. Brit Mollenhauer and Prof. Wolfgang Oertel and their teams in Göttingen, Kassel, and Marburg, explored the question of whether the early events in the course of the disease also change the microbiome at the two likely ports of entry. They took samples from the nose and gut of 76 Parkinson's patients and 78 healthy control people (who are taking part in a long-term study). They also examined the microbiome of 21 subjects diagnosed with Idiopathic Rapid-Eye-Movement Sleep Behaviour Disorder (iRBD), because iRBD patients have a greatly elevated risk of developing Parkinson's disease later in life.

The results showed that the gut bacterial community differed considerably between all three groups. "Parkinson's patients could be differentiated from healthy controls by their respective gut bacteria," explained first-author Dr. Anna Heintz-Buschart. And the majority of the differential bacteria showed similar trends in the iRBD group. For example, certain bacterua were more prevalent in one group while the count was lower in others. In the samples from the subjects' nasal cavities, however, the researchers found no such differences. Certain gut microbes were also associated with non-motor Parkinson's symptoms, for example depression.

"We hope that, by comparing the groups, we will learn to better understand the role of the microbiome in the process of the disease and to find out what changes occur and when," Paul Wilmes explained, "This might deliver new starting points for early treatment of the disease. It would also be essential knowledge for one day being able to use the absence or presence of certain bacteria as a biomarker for early detection of the disease."

The study, by Heintz-Buschart A et al, was published August 26, 2017, in the journal Movement Disorders.

Related Links:
University of Luxembourg



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.